Allurion Technologies

Allurion has submitted the first three modules of its premarket approval (PMA) application to the U.S. FDA for the Allurion Balloon, the world’s first swallowable, procedureless™ gastric balloon for weight loss.   This marks a critical step for #Allurion, and we are pleased to capitalize on the opportunity that the FDA provides through its modular submission program to improve the efficiency of our application process.   The Company expects to file the fourth and final module of the PMA containing the clinical data from its AUDACITY trial early next year. https://lnkd.in/gv8C-xju

At the beginning of the year, the BBC was in attendance to document and broadcast David Pulford’s balloon placement, as he was one of the first patients to receive the Allurion Gastric Balloon through the NHS at Musgrove Park Hospital. The Allurion Balloon was used to help him reach a safe and suitable weight, that would enable him to undergo lifesaving surgery. After losing three and a half stone (22.2kg), the BBC came back to follow David’s weight loss journey as he underwent a gastric bypass with Dr Hamish Noble, who said the balloon treatment was a "useful tool for the team". To read the article, click here : https://lnkd.in/esxJXWcW To read the original article about David’s Allurion Balloon placement experience, click here: https://lnkd.in/eKWNuKQP

🌟 We're thrilled to share that our latest study shows patients on the Allurion Program achieving an average weight loss of 14% while gaining 5.6% in lean body mass over just four months. This groundbreaking data highlights our commitment to innovative, effective weight loss solutions. 🌟 Key highlights: 📊 Average weight loss: 13.9 kg 🏋️ Lean mass gain: 2.8 kg 📉 Body fat reduction: from 32.7% to 27.9% Dr. Shantanu Gaur, Founder and CEO, says, “These findings prove significant weight loss without losing muscle mass is possible with Allurion's advanced tech and personalized care.” Join us in celebrating this milestone on our journey to end obesity. #Allurion #WeightLoss #HealthTech #Innovation #LeanMassGain #ObesityTreatment #AI #VirtualCare To read the full press release, click here: https://lnkd.in/e3HFQ7Rz

We're proud to announce today three scientific presentations at the American Society for Metabolic and Bariatric Surgery Annual Meeting (ASMBS) taking place in San Diego, California, June 9-13, 2024. Data from a study of 121 patients across 11 obesity centers treated with two consecutive, four-month Allurion Balloons showed patients achieved 22.1% weight loss on average at one year. "We believe these findings underscore the potential of the Allurion Balloon to deliver superior outcomes to other intragastric balloons, approaching those of weight loss surgery, for patients seeking effective and safe weight loss solutions", said Dr. Shantanu Gaur, Founder and CEO of Allurion. To read the full press release, click here: https://lnkd.in/eckka4pf

We're glad to announce the expansion of our Artificial Intelligence (AI)-powered weight loss coach, Coach Iris, to support patients prescribed GLP-1s and other anti-obesity medications and the first commercial agreements for our Virtual Care Suite (VCS) in the United States.  With this update to Coach Iris, patients now have access to 24/7 personalized coaching and guidance specific to GLP-1s and other anti-obesity medications, such as treatment duration, side effects, and consequences of stopping their treatment. They can also engage with Coach Iris for tailored meal plans, recipes, exercise routines, stress management techniques, and motivational insights. To read the full press release, click here: https://lnkd.in/gvk5WfWM Shantanu Gaur Brian Conyer Chris Martinez Zoe Griffiths Martha Neary Jen Pain

Our Chief Executive Officer, Shantanu Gaur, and Chief Financial Officer, Christopher Geberth, will participate in a fireside chat with Matt Taylor, CFA, Managing Director at Jefferies, during the Jefferies Global Healthcare Conference, which will be held in New York City on June 5–6, 2024. Management will also participate in 1x1 meetings. The fireside chat is scheduled for Wednesday, June 5, 2024 at 1:30 p.m. Eastern Time, and will be accessible via a live webcast here: https://lnkd.in/gFqV9xS2. The webcast replay will be available after the conclusion of the live presentation on the Company’s website: https://lnkd.in/gfjiTA6a Allurion will also attend the Sidoti Small Cap Virtual Conference on June 12-13, where management will participate in 1x1 meetings. Shantanu Gaur and Chris Geberth will deliver a presentation on Thursday, June 13, 2024 at 10:00 a.m. Eastern Time. The presentation will be accessible via a live webcast on the Company’s website, where the replay will also be available after the conclusion of the live presentation. To read the full press release, click here: https://lnkd.in/gDCC2Bnj 

✌🏼 5 DAYS TO GO! We’re excited to invite you to our next virtual masterclass of 2024 taking place on Wednesday, May 22nd. Zoe Griffiths, Senior Director of Behavioral Medicine, and Martha Neary, Senior Manager of Behavioral Medicine, will present ‘Mastering Body Composition: Maximizing Fat Loss while Safeguarding Lean Muscle Mass’. This event promises to delve into the intricacies of achieving optimal weight loss results for your patients, explaining: ⭐ Why focusing on fat loss matters ⭐ How to monitor and assess the quality of weight loss in your patients ⭐ NEW data on fat loss throughout the Allurion Program ⭐ How to assist patients in optimizing their fat loss while preserving Lean Body Mass After the masterclass you will have the chance to ask live questions. The masterclass will be presented in English but live translation in Spanish, French, Italian and Turkish will be available. ❔ How do I register? We’re delighted to be able to offer two different sessions to suit your availability on May 22nd. Reserve your spot today by clicking one of the options below. Interested in joining but can’t attend? Don’t worry - please still register to receive an on-demand link following the webinar. Session 1 👉🏼 06:00 EDT / 11:00 GMT / 12h CET: https://lnkd.in/dWb_pzFh Session 2 👉🏼 12:00 EDT / 17:00 GMT / 18h CET: https://lnkd.in/d-7SYfic #Allurion #AllurionProgram #Obesity #GastricBalloon #BodyComposition #WeightLoss

We’re proud to announce three scientific presentations at the 31st European Congress on Obesity (ECO) held in Venice, Italy, on 12-15 May, 2024. Presentations include data from a study of 712 patients treated with the Allurion Program, which is anchored by the Allurion Balloon and enhanced by the Virtual Care Suite featuring Allurion’s proprietary behavior change program. This study was conducted at six obesity centers in six countries, and the data showed patients achieved total body weight loss (TBWL) of 14.1% on average at 4 months, 70% of which came from fat mass and only 30% of which came from lean body mass.    “The Allurion Program was designed to monitor both weight loss and lean body mass, facilitate basic changes in behavior that can protect skeletal muscle, and reduce the impact on lean body mass during periods of rapid weight loss,” said Dr. Shantanu Gaur, Founder and CEO of Allurion. To read the full press release and learn more about the findings, click here: https://lnkd.in/ebf9-2ku #Allurion #AllurionProgram #WeightLoss #Obesity #ECO #GastricBalloon

🎉 We're thrilled to announce a significant milestone at The Gastric Balloon Group: 2,500 Allurion Balloon procedures completed! 🎉   We're incredibly proud of our dedicated team and the impact they've made on the lives of our patients. Each procedure represents a step towards improved health and well-being for those on their weight loss journey.   To our patients: thank you for entrusting us with your care. Here's to the next 2,500 procedures and beyond! #GastricBalloonGroup #Allurion #WeightLossJourney #HealthAndWellness Allurion Technologies

Last week, our digital health team at Allurion attended the annual OMA (Obesity Medicine Association) conference in Denver, US, to formally launch the Allurion Virtual Care Suite for US weight loss clinics and providers offering anti-obesity medication therapy, bariatric surgery, and other weight loss devices. “The incredible response we received at the OMA conference further confirmed the immense demand from providers treating obesity. We are excited to support our newest US-based customers in helping them provide exceptional care and weight loss outcomes for their patients.” – Brian Conyer, VP Digital Health. Stay tuned for future updates on the expansion of the Allurion VCS across the US! Jen Pain Zoe Griffiths #Allurion #AllurionProgram #Obesity #GastricBalloon #WeightLoss #VirtualCareSuite #AllurionVCS #DigitalHealth